Home/Pipeline/AI Biomarkers for Lung Cancer

AI Biomarkers for Lung Cancer

Lung Cancer

UnknownActive

Key Facts

Indication

Lung Cancer

Phase

Unknown

Status

Active

Company

BioAI Health

About BioAI Health

BioAI Health is a private, pre-revenue AI-driven biotech company developing the PredictX platform, a multimodal causal AI system designed to analyze complex biomedical data including histopathology, spatial transcriptomics, and single-cell RNA sequencing. The company operates a hybrid business model, offering AI biomarker discovery services, data sourcing, and computational pathology expertise to biopharma partners, positioning itself as an enabler for faster, more precise drug development and diagnostics. With a leadership team boasting decades of industry experience, BioAI aims to translate AI insights into novel digital diagnostic assays and therapeutic targets, primarily in oncology, starting with lung cancer.

View full company profile

Therapeutic Areas

Oncology

Other Lung Cancer Drugs

Drug	Company	Phase	Status
OncoStrong™	Lamark Biotech	Preclinical	Active
15dPMJ2	Claradele Pharmaceuticals	Research	Exploratory (Pathway Implied)
SUPLEXA	Alloplex Biotherapeutics	Phase 1	Completed
Oncology Digital Biomarkers	Imvaria	Development	Active
Aerosolized Platinum Nanoparticles	HylaPharm	Pre-clinical	Active
ENV105	Kairos Pharma	Phase 1	Active
AI for Lung Cancer	Invenio Imaging	Research	Active
Liposome Program	NanoTech Pharma	Preclinical/Phase 1/2	Active
Dendritic Cell Vaccine	MegaNano BioTech	Pre-clinical	Active
PRDM2 Target	ARIZ Precision Medicine	Preclinical	Active
ZEN-3694	Zenith Epigenetics	Proof-of-Concept	Active
TEC-001 + Keytruda	Teclison	Phase 2	Active